{
    "nct_id": "NCT06128044",
    "official_title": "A Phase 1, Multicenter, Open-Label Study of CB-012, a CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia",
    "inclusion_criteria": "* Documented diagnosis of AML with either refractory or relapsed disease,\n* Non-proliferative disease\n* No more than 3 prior lines of therapy (induction, consolidation with or without allogeneic stem cell transplant, and maintenance are considered 1 line of therapy)\n* No available therapy with reasonable survival benefit\n* Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1 and fit for allogeneic stem cell transplant\n* Adequate renal, hepatic, pulmonary, and cardiac function, with specific laboratory criteria\n* Women of child-bearing potential and men with a female partner who has child-bearing potential must agree to use acceptable, effective methods of birth control.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Acute promyelocytic leukemia\n* Extra-medullary disease (EMD) that is metabolically inactive by 18-FDG PET-CT\n* Prior treatment with CAR-T cell therapy\n* Allogeneic stem cell transplant within 100 days before lymphodepletion\n* Active graft-vs-host disease requiring therapy\n* Known active or prior history of central nervous system involvement\n* Seropositive for or history of human immunodeficiency virus (HIV)\n* Vaccinated with live, attenuated vaccine within 4 weeks prior to lymphodepletion\n* Active hepatitis B or C infection\n* Primary immunodeficiency or autoimmune disease\n* Known life-threatening allergies, hypersensitivity, or intolerance to CB-012 or its excipients\n\nOther inclusion and exclusion criteria may apply.",
    "miscellaneous_criteria": ""
}